跳转至内容
Merck
CN

Y0000226

Moxonidine

European Pharmacopoeia (EP) Reference Standard

别名:

4-Chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methyl-5-pyrimidinamine

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C9H12ClN5O
化学文摘社编号:
分子量:
241.68
UNSPSC Code:
41116107
NACRES:
NA.24
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

SMILES string

Clc1nc(nc(c1N=C2NCCN2)OC)C

InChI

1S/C9H12ClN5O/c1-5-13-7(10)6(8(14-5)16-2)15-9-11-3-4-12-9/h3-4H2,1-2H3,(H2,11,12,15)

InChI key

WPNJAUFVNXKLIM-UHFFFAOYSA-N

grade

pharmaceutical primary standard

API family

moxonidine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

正在寻找类似产品? 访问 产品对比指南

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Moxonidine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Scintigraphic diagnosis of Erdheim-Chester disease.
Hans Balink et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29(16), e470-e472 (2011-03-23)
Angelita Maria Stabile et al.
Life sciences, 88(11-12), 493-503 (2011-02-01)
Heart failure is a progressive deterioration in heart function associated with overactivity of the sympathetic nervous system. The benefit of inhibition of sympathetic activity by moxonidine, a centrally acting imidazoline receptor agonist, was questioned based on the outcome of a
Lincoln P Edwards et al.
Cardiovascular therapeutics, 30(4), 199-208 (2011-09-03)
The sympathetic nervous system plays a central role in the pathophysiology not only of hypertension and other cardiovascular diseases but also metabolic disorders including disturbances of glucose and lipid homeostasis. A centrally acting sympathetic agent is therefore attractive not only
Jun-Feng Peng et al.
Cardiovascular research, 89(2), 473-481 (2010-09-11)
The depressor action of the centrally antihypertensive drug moxonidine has been attributed to activation of I(1)-imidazoline receptor in the rostral ventrolateral medulla (RVLM). The objective of this study was to determine the role of the γ-aminobutyric acid (GABA) mechanisms in
L T Totola et al.
Neuroscience, 250, 80-91 (2013-07-16)
The rostral ventrolateral medulla (RVLM) contains the presympathetic neurons involved in cardiovascular regulation that has been implicated as one of the most important central sites for the antihypertensive action of moxonidine (an α2-adrenergic and imidazoline agonist). Here, we sought to

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持